Assessment of the utility of patient outcome measures in rheumatoid arthritis

Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376(9746):1094-108. Available from: https://doi.org/10.1016/S0140-6736(10)60826-4

Boyd TA, Bonner A, Thorne C, Boire G, Hitchon C, Haraoui BP, et al. The relationship between function and disease activity as measured by the HAQ and DAS28 varies over time and by rheumatoid factor status in early inflammatory arthritis (EIA). Results from the CATCH Cohort. The Open Rheumatology Journal 2013;7:58-63. Available from: https://doi.org/10.2174/1874312901307010058

Gabay C, Hasler P, Kyburz D, So A, Villiger P, von Kempis J, et al. Biological agents in monotherapy for the treatment of rheumatoid arthritis. Swiss Medical Weekly 2014;144:w13950. Available from: https://doi.org/10.4414/smw.2014.13950

National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed. Technology appraisal guidance [TA375] 2016 Available from: https://www.nice.org.uk/guidance/ta375 (accessed 12.06.2020).

British Medical Association, Royal Pharmaceutical Society of Great Britain, National Institute for Health and Care Excellence. British National Formulary [electronic resource]. BNF.